Well, I brought into the stock only a few months back, on Southern Cross
Report. The more I read about MSB, the more I see the huge upside here and the application of their ground braking technology.
I think we will see more than the $11 predicted by end of year, as clinical trial results are more than amazing to date.
MSB has rallied hard now, so what else is about in the Biotech stocks.
Who will be the next MSB in the biotech sector.
My three picks are:
PRR: cervical cancer vaccine potential. Clinical Stage 2b. NASDAQ listing in weeks is my prediction.
TIS: Ulcer and wound treatment. Big Deal not far away at all.
ADO: Microcap, already has commercial deal. Diagnostics. Many more commercial deals to come. revenue and cost advantages, proven technology, at a lower cost base.
Love to hear your thoughts. DYOR
the next mesoblast
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.39 |
Change
-0.005(0.36%) |
Mkt cap ! $1.581B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.42 | $1.38 | $4.391M | 3.156M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 48253 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 32922 | 2 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |